1. In the past 3 months, how many metastatic melanoma patients were treated by your Trust?
a. Dabrafenib
b. Dabrafenib + Trametinib
c. Densoumab
d. Encorafenib + Binimetinib
e. Ipilimumab
f. Ipilimumab + Nivolumab
g. Nivolumab
h. Pembrolizumab
i. Trametinib
j. Vemurafenib
k. Vemurafenib + Cobimetinib
l. Other active systemic anti-cancer therapy
Palliative care only
2. Within your health trust how many patients are currently [within the past 3 months] being treated for metastatic Non-small-cell lung cancer (NSCLC) with the following:
a. Afatinib
b. Atezolizumab monotherapy or combination
c. Brigatinib
d. Ceretinib
e. Crizotinib
f. Docetaxel monotherapy or combination
g. Erlotinib
h. Gefitinib
i. Gemcitabine
j. Nitendanib + docetaxel
k. Nivolumab
l. Osimertinib
m. Paclitaxel
n. Pembrolizumab monotherapy
o. Pembrolizumab chemo in combination
p. Pembrolizumab monotherapy
q. Pemetrexed monotherapy or combination
r. Ramucirumab
s. Vinorelbine monotherapy or combination
t. Other active systemic anti-cancer therapy
u. Palliative care only
3. Out of the metastatic NSCLC patients currently [within the past 3 months] being treated, are you able to provide the number of patients being treated for Squamous Cell Non-small-cell lung cancer (SqNSCLC ) with the following products?
a. Afatinib
b. Atezolizumab monotherapy or combination
c. Brigatinib
d. Ceretinib
e. Crizotinib
f. Docetaxel monotherapy or combination
g. Erlotinib
h. Gefitinib
i. Gemcitabine
j. Nitendanib + docetaxel
k. Nivolumab
l. Osimertinib
m. Paclitaxel
n. Pembrolizumab monotherapy
o. Pembrolizumab chemo in combination
p. Pembrolizumab monotherapy
q. Pemetrexed monotherapy or combination
r. Ramucirumab
s. Vinorelbine mono or combination
t. Other active systemic anti-cancer therapy
u. Palliative care only
